Long Term Tolerability and AR Pathway Inhibitor Selection in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce to discuss how long term tolerability influences the selection of androgen receptor pathway inhibitors for patients with metastatic castration sensitive prostate cancer (mCSPC). Dr. Bryce explains that because many patients remain on systemic therapy for several years, clinicians must consider the cumulative impact of treatment related adverse effects when choosing a regimen. He highlights that fatigue, metabolic changes, cardiovascular risk, and other chronic toxicities can significantly affect patient quality of life over time. As a result, treatment selection often involves balancing the demonstrated efficacy of therapy with its long term safety profile and the patient’s baseline health status. Dr. Bryce also notes that careful monitoring and proactive management of adverse effects are essential to help patients remain on therapy and maintain treatment benefit.